Clinical Pharmacology & Therapeutics · 2009 · 238 citations · 23 references
MedicinePharmacologyPsychiatryChild DevelopmentNeuropharmacologyPsychopharmacologyAntidepressant PharmacologyAntidepressant PharmacotherapyDevelopmental NeuropharmacologyPerinatal PharmacologyPrenatal DevelopmentSerotonergic PharmacologyAntidepressant Use In PregnancyClinical Pharmacology EvidenceMaternal Mood DisordersNeurobehavioral DevelopmentNeurodevelopmental Outcomes After Prenatal ExposurePrenatal Drug ExposurePrenatal NeuropharmacologySerotonergic Mechanisms
Selective serotonin reuptake inhibitor (SSRI) antidepressants are frequently used in the management of antenatal maternal mood disturbances. SSRIs readily cross the placenta and increase central serotonergic tone in the fetus. Given serotonin's key neurodevelopmental role, such prenatal exposure raises concerns about its impact on child development. Preclinical studies report enduring molecular, physiological, and behavioral consequences of developmental SSRI exposure. In humans, sustained developmental outcomes remain largely unstudied, and distinguishing between the effects of prenatal SSRI exposure and the impact of maternal mental illness remains a key challenge.
23
Early-Life Blockade of the 5-HT Transporter Alters Emotional Behavior in Adult Mice
Mark S. Ansorge, Ming‐Ming Zhou, Alena Lira et al. · Science · 2004 · 829 citations
Medicine, Neuroscience, Pharmacology +17
Neurodevelopment of Children Exposed in Utero to Antidepressant Drugs
Irena Nulman, Joanne Rovet, Donna E. Stewart et al. · New England Journal of Medicine · 1997 · 578 citations · Full text
Medicine, Pediatrics, Psychiatry +17
Tim F. Oberlander, William Warburton, Shaila Misri et al. · Archives of General Psychiatry · 2006 · 548 citations
Medicine, Obstetrics, Psychiatry +16